Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ARN-6039 in Healthy Adults
NCT03237832Phase 1Completed
- Sponsor
- Arrien Pharmaceuticals LLC
- Start
- May 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of arn-6039 in multiple sclerosis (MS) (5 cohorts), sponsored by Arrien Pharmaceuticals LLC. Primary endpoint: Change in clinical tests results, vital signs, physical assessment, ECGs, and incidence of Adverse Events. Started May 2016; status: completed.
02
Drugs
arn-6039
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03237832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237832.